Clinical Trials
8 trialsNCT06802835 2026-05-11
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06475300 2026-05-06
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT06437522 2025-05-07
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04830267 2024-03-28
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT06170710 2023-12-14
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT04778956 2021-03-04
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting